ClinicalTrials.gg
TerminatedNCT05081882Updated Sep 3, 2026Results posted

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

A Phase 2 interventional study of Kava and Placebo in Smoking, sponsored by University of Florida. Terminated at 1 site in United States. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
slow accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.

Enrollment
698th of 785
19 · median 109
Started
2022
with 44 others
Phase 2
75 of 899
10 open now
Registered
737th of 899
by date

Among the 899 studies in Smoking with a site in United States, this one is the 698th largest by enrollment of the 785 interventional ones that give a count, is one of 45 that started in 2022, is one of 75 in phase 2, and was the 737th registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 899 studies in Smoking with a site in United States, or all of them as a file.
02

Study summary

Tobacco use is the leading cause of many preventable diseases, particularly lung cancer. Based on the national cancer data in 2020, Florida has the highest lung cancer incidence (18,150 cases) with the most deaths (10,580 deaths) among all the states in the United States. Unfortunately, around 16% of adults in Florida continue to smoke cigarettes due to its addictive nature and the limited success of current cessation strategies. Therefore, there is an unmet and urgent need for novel interventions to improve the success of tobacco cessation. If such an intervention can reduce tobacco-associated lung carcinogenesis, that will be more desirable. The ultimate goal of this study is to develop a safe and effective kava-based intervention to enable tobacco cessation and reduce lung cancer risk, which will improve the health of Floridians.

This study will evaluate the compliance with a daily kava regimen among active smokers who have no intention to quit smoking. This study will also investigate whether kava use can reduce tobacco use and dependence, as well as tobacco-associated lung carcinogenesis.

03

Conditions studied

  • Smoking

Keywords

  • tobacco dependence
  • smoking cessation
  • kava
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults aged 21 years or above
  • self-reported smoking at least 5 cigarettes/day for the past year with no intention to quit at time of screening visit
  • expired carbon monoxide level of more than 8 ppm at recruitment
  • willingness to participate in the proposed study, as indicated by signed
  • access to a functional telephone
  • expected presence in the study's geographical area for the next 4 months
  • not currently enrolled in any smoking cessation programs per self-report
  • female subjects of will be required to practice acceptable methods of (the acceptable methods of birth control include birth control pills, Birth Control Shot, Birth Control Implant, Intrauterine Device [IUD], Diaphragm, and cervical cap)

Exclusion criteria

Exclusion Criteria:

  • history of active cancer (other than non-melanoma skin cancer) within the past 2 years
  • diagnosed with liver dysfunction or with previous liver diseases
  • levels of , aspartate transaminase, alkaline phosphatase, or total over limit of normal range at prescreen
  • inability to refrain from acetaminophen, alcohol (no more than one drink daily via self-report)
  • are pregnant or nursing (lactating) or of childbearing age planning to become pregnant or unwilling to use adequate during the study
  • participant answered "Yes" to any of the ASQ questions 1 through 3, or refuses to answer all of the questions. If subject answers 'Yes' to question 4 but the most recent suicide attempt took place more than12 months from screening visit then subject is still eligible.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Kava Intervention

    Drug: Kava

  • Placebo comparator
    Placebo Control

    Drug: Placebo

Interventions

  • DrugPiper methysticum rootStudies of Piper methysticum rootPiper methysticum root pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.

  • DrugPlacebo

    Participants on this arm will take one placebo capsule orally three times daily for 28 days.

06

What researchers measure

Primary outcomes

  1. Urinary Total Nicotine Equivalents

    Measure urinary total nicotine equivalents (TNE). TNE is the sum of nicotine and its metabolites in a participant's urine. TNE was measured at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.

    Time frame: at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.

Secondary outcomes

  1. Reinforcing Effects of Smoking

    Determine if participants experience reinforcing effects of smoking using the Modified Cigarette Evaluation Questionnaire. Subjects respond with a whole number numerical value from 1 to 7 for each item. The item responses are used to determine 5 scores: smoking satisfaction, psychological reward, aversion, enjoyment of respiratory tract sensations and craving reduction. Each score is either the response to a single item (for the enjoyment of respiratory tract sensations and craving reduction scores) or is calculated as the mean of multiple individual item responses (for the smoking satisfaction, psychological reward, and aversion scores). Possible values for each score range from a minimum of 1 and a maximum of 7. A higher value is worse for the smoking satisfaction, psychological reward and craving reduction scores. A lower value is worse for the aversion score. A higher score for the respiratory tract sensations score means greater enjoyment of respiratory tract sensations.

    Time frame: At baseline (Day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after starting treatment)

  2. Participant Reported Number of Cigarettes Smoked Weekly

    Determine the participant reported number of cigarettes smoked weekly. The number of cigarettes smoked was measured by having participants document how many cigarettes they smoked in the past week on a calendar. Participants completed this at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

    Time frame: At baseline (day 1) of treatment, at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)

  3. Participant Urge to Smoke

    Measure participant urge to smoke using the Brief Questionnaire on Smoking Urges (QSU-Brief). The QSU-Brief is a 10-item scale, assessing the features of craving, including the anticipation of relief of nicotine withdrawal, anticipation of positive outcomes of smoking, desire to smoke, and intention to smoke. Participants respond with a score from 1 (best) to 7 (worst) for each item. Possible total scores range from 10 to 70, with a higher score meaning a greater urge to smoke. Participants completed the QSU-Brief at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

    Time frame: At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)

  4. Nicotine Dependency

    Measure participant nicotine dependency using the Fagerström Test for Nicotine Dependence (FTND). The FTND is a 6-item scale measuring the level of nicotine dependency or addiction. It assesses how soon tobacco use begins each day, which cigarettes during the day a person could do without, how smokers cope in places where they cannot smoke, and how frequently and how deeply they smoke. Responses for each item are given either 0 points or 1 point for 4 items and 0-3 points for 2 items, with more points meaning a greater nicotine dependency. Possible total scores range from 0 to 10 points, with a higher score meaning a greater nicotine dependency. Participants completed the FTND at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

    Time frame: At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)

  5. Perceived Stress

    Measure participant perceived stress using the Perceived Stress Scale (PSS). The PSS is a 10-item scale measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. The scale also includes a number of direct queries about current levels of experienced stress. Participants respond to each item with a score of 0 ("never") to 4 ("very often"). A higher score is worse for the 6 items assessing negative outcomes, such as how often participants felt nervous and stressed and a lower score is worse for the 4 items assessing positive outcomes, such as how often participants felt on top of things. Possible total scores range from 0 to 40, with a higher score meaning higher perceived stress. Participants completed the PSS at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

    Time frame: At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)

  6. Severity of Insomnia

    Measure severity of participant insomnia using the Insomnia Severity Scale. The Insomnia Severity Scale is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. Participants respond to each item with a score of 0 (best) to 4 (worst). Possible total scores range from 0 to 28, with a higher score meaning more severe insomnia. Participants completed the Insomnia Severity Scale at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

    Time frame: At baseline (day 1) of treatment, at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)

  7. Compliance Score Percentage

    Evaluate subject compliance with the kava intervention, as measured by the compliance score percentage. The compliance score percentage was calculated by dividing the total number of kava or placebo capsules actually consumed across all visits by the total number of kava or placebo capsules expected to be consumed across all visits and multiplying the result by 100.

    Time frame: At end of treatment (28 days after starting treatment)

  8. Participant Compliance Status

    Determine participant compliance status, defined as whether the number of kava or placebo capsules expected to be returned matched the number of kava or placebo capsules actually returned by a participant across all visits, with "Yes" indicating a match and "No" indicating a mismatch.

    Time frame: At end of treatment (28 days after starting treatment)

07

Results

Posted Sep 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneKava InterventionPlacebo Control
Started910
Completed910
Not completed00

Outcome measures

PrimaryUrinary Total Nicotine Equivalents

Measure urinary total nicotine equivalents (TNE). TNE is the sum of nicotine and its metabolites in a participant's urine. TNE was measured at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.

Time frame:
at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.
Reported as:
Mean · nmol/mg creatinine
Urinary Total Nicotine Equivalents
nmol/mg creatinineKavaPlacebo
Baseline68.72 (57.49 to 79.94)64.53 (48.75 to 80.32)
After 1 week on treatment77.84 (59.20 to 96.48)63.59 (48.51 to 78.68)
After 2 weeks on treatment95.45 (67.48 to 123.41)67.98 (49.27 to 86.68)
End of treatment74.28 (57.10 to 91.47)59.43 (43.16 to 75.70)
4 weeks after end of treatment76.68 (57.25 to 96.11)72.22 (50.58 to 93.85)
8 weeks after end of treatment95.21 (72.21 to 118.22)70.28 (53.30 to 87.26)
SecondaryReinforcing Effects of Smoking

Determine if participants experience reinforcing effects of smoking using the Modified Cigarette Evaluation Questionnaire. Subjects respond with a whole number numerical value from 1 to 7 for each item. The item responses are used to determine 5 scores: smoking satisfaction, psychological reward, aversion, enjoyment of respiratory tract sensations and craving reduction. Each score is either the response to a single item (for the enjoyment of respiratory tract sensations and craving reduction scores) or is calculated as the mean of multiple individual item responses (for the smoking satisfaction, psychological reward, and aversion scores). Possible values for each score range from a minimum of 1 and a maximum of 7. A higher value is worse for the smoking satisfaction, psychological reward and craving reduction scores. A lower value is worse for the aversion score. A higher score for the respiratory tract sensations score means greater enjoyment of respiratory tract sensations.

Time frame:
At baseline (Day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after starting treatment)
Reported as:
Mean · score
Reinforcing Effects of Smoking
scoreKava ArmPlacebo Arm
Smoking Satisfaction Score (Baseline)3.44 ± 1.263.95 ± 1.38
Psychological Reward Score (Baseline)3.49 ± 1.014.08 ± 1.41
Aversion Score (Baseline)1.33 ± 0.832.10 ± 0.91
Enjoyment of Respiratory Tract Sensations Score (Baseline)2.78 ± 1.391.60 ± 0.52
Craving Reduction Score (Baseline)4.22 ± 1.724.00 ± 1.94
Smoking Satisfaction Score (1 week after beginning treatment)2.93 ± 1.373.47 ± 0.98
Psychological Reward Score (1 week after beginning treatment)2.84 ± 0.663.48 ± 1.38
Aversion Score (1 week after beginning treatment)1.78 ± 1.092.15 ± 1.25
Enjoyment of Respiratory Tract Sensations Score (1 week after beginning treatment)2.44 ± 1.741.80 ± 0.92
Craving Reduction Score (1 week after beginning treatment)4.11 ± 1.624.40 ± 1.65
Smoking Satisfaction Score (2 weeks after beginning treatment)2.59 ± 1.423.37 ± 1.11
Psychological Reward Score (2 weeks after beginning treatment)2.80 ± 1.452.93 ± 1.61
Aversion Score (2 weeks after beginning treatment)2.06 ± 1.941.94 ± 0.88
Enjoyment of Respiratory Tract Sensations Score (2 weeks after beginning treatment)2.63 ± 1.921.78 ± 0.83
Craving Reduction Score (2 weeks after beginning treatment)3.44 ± 2.243.67 ± 1.80
Smoking Satisfaction Score (End of treatment)2.42 ± 1.292.96 ± 1.36
Psychological Reward Score (End of treatment)2.80 ± 1.402.62 ± 1.36
Aversion Score (End of treatment)1.50 ± 1.221.78 ± 0.83
Enjoyment of Respiratory Tract Sensations Score (End of treatment)2.13 ± 1.131.89 ± 1.05
Craving Reduction Score (End of treatment)3.75 ± 2.123.56 ± 2.30
SecondaryParticipant Reported Number of Cigarettes Smoked Weekly

Determine the participant reported number of cigarettes smoked weekly. The number of cigarettes smoked was measured by having participants document how many cigarettes they smoked in the past week on a calendar. Participants completed this at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

Time frame:
At baseline (day 1) of treatment, at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Reported as:
Mean · cigarettes smoked weekly
Participant Reported Number of Cigarettes Smoked Weekly
cigarettes smoked weeklyKava ArmPlacebo Arm
Baseline18.74 ± 8.6018.99 ± 9.97
1 week after beginning treatment19.06 ± 13.4515.01 ± 8.68
2 weeks after beginning treatment18.75 ± 15.6411.14 ± 7.90
End of treatment18.02 ± 17.2510.83 ± 8.21
SecondaryParticipant Urge to Smoke

Measure participant urge to smoke using the Brief Questionnaire on Smoking Urges (QSU-Brief). The QSU-Brief is a 10-item scale, assessing the features of craving, including the anticipation of relief of nicotine withdrawal, anticipation of positive outcomes of smoking, desire to smoke, and intention to smoke. Participants respond with a score from 1 (best) to 7 (worst) for each item. Possible total scores range from 10 to 70, with a higher score meaning a greater urge to smoke. Participants completed the QSU-Brief at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

Time frame:
At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Reported as:
Mean · score on a scale
Participant Urge to Smoke
score on a scaleKava ArmPlacebo Arm
Total score - Baseline34.89 ± 15.9531.30 ± 19.03
Total score - 1 week after beginning treatment27.56 ± 12.7317.10 ± 6.76
Total score - 2 weeks after beginning treatment25.67 ± 13.6418.78 ± 8.58
Total score - End of treatment22.13 ± 13.2314.67 ± 3.24
SecondaryNicotine Dependency

Measure participant nicotine dependency using the Fagerström Test for Nicotine Dependence (FTND). The FTND is a 6-item scale measuring the level of nicotine dependency or addiction. It assesses how soon tobacco use begins each day, which cigarettes during the day a person could do without, how smokers cope in places where they cannot smoke, and how frequently and how deeply they smoke. Responses for each item are given either 0 points or 1 point for 4 items and 0-3 points for 2 items, with more points meaning a greater nicotine dependency. Possible total scores range from 0 to 10 points, with a higher score meaning a greater nicotine dependency. Participants completed the FTND at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

Time frame:
At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Reported as:
Mean · score on a scale
Nicotine Dependency
score on a scaleKava ArmPlacebo Arm
Total score - Baseline6.00 ± 1.875.80 ± 2.15
Total score - 1 week after beginning treatment5.33 ± 2.004.90 ± 1.91
Total score - 2 weeks after beginning treatment5.11 ± 3.064.11 ± 1.62
Total score - End of treatment4.50 ± 3.074.56 ± 1.67
SecondaryPerceived Stress

Measure participant perceived stress using the Perceived Stress Scale (PSS). The PSS is a 10-item scale measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. The scale also includes a number of direct queries about current levels of experienced stress. Participants respond to each item with a score of 0 ("never") to 4 ("very often"). A higher score is worse for the 6 items assessing negative outcomes, such as how often participants felt nervous and stressed and a lower score is worse for the 4 items assessing positive outcomes, such as how often participants felt on top of things. Possible total scores range from 0 to 40, with a higher score meaning higher perceived stress. Participants completed the PSS at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

Time frame:
At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Reported as:
Mean · score on a scale
Perceived Stress
score on a scaleKava ArmPlacebo Arm
Total score - Baseline20.22 ± 7.6118.40 ± 11.65
Total score - 1 week after beginning treatment16.67 ± 7.1616.50 ± 11.28
Total score - 2 weeks after beginning treatment17.78 ± 7.6114.44 ± 10.81
Total score - End of treatment16.63 ± 7.5615.11 ± 10.87
SecondarySeverity of Insomnia

Measure severity of participant insomnia using the Insomnia Severity Scale. The Insomnia Severity Scale is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. Participants respond to each item with a score of 0 (best) to 4 (worst). Possible total scores range from 0 to 28, with a higher score meaning more severe insomnia. Participants completed the Insomnia Severity Scale at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.

Time frame:
At baseline (day 1) of treatment, at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Reported as:
Mean · score on a scale
Severity of Insomnia
score on a scaleKava ArmPlacebo Arm
Total score - Baseline12.00 ± 7.2812.80 ± 6.73
Total score - 1 week after beginning treatment7.33 ± 5.727.90 ± 7.06
Total score - 2 weeks after beginning treatment8.33 ± 6.937.44 ± 6.52
Total score - End of treatment7.13 ± 7.167.56 ± 8.23
SecondaryCompliance Score Percentage

Evaluate subject compliance with the kava intervention, as measured by the compliance score percentage. The compliance score percentage was calculated by dividing the total number of kava or placebo capsules actually consumed across all visits by the total number of kava or placebo capsules expected to be consumed across all visits and multiplying the result by 100.

Time frame:
At end of treatment (28 days after starting treatment)
Reported as:
Mean · percentage
Compliance Score Percentage
percentageKava ArmPlacebo Arm
Compliance Score Percentage97.6 ± 2.898.3 ± 3.5
SecondaryParticipant Compliance Status

Determine participant compliance status, defined as whether the number of kava or placebo capsules expected to be returned matched the number of kava or placebo capsules actually returned by a participant across all visits, with "Yes" indicating a match and "No" indicating a mismatch.

Time frame:
At end of treatment (28 days after starting treatment)
Reported as:
Count of participants · Participants
Participant Compliance Status
ParticipantsKava ArmPlacebo Arm
Yes47
No53

Adverse events

Collected over Adverse events were collected from the date on which the first kava or placebo capsules were dispensed to the participant until the Week 12 follow-up visit. Adverse event data were collected for a maximum of 12 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Kava Intervention0/9 (0%)0/9 (0%)1/9 (11.1%)
Placebo Control0/10 (0%)0/10 (0%)5/10 (50%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventKava InterventionPlacebo Control
Aspartate aminotransferase increasedInvestigations0/92/10
Alanine aminotransferase increasedInvestigations0/92/10
HeadacheNervous system disorders0/92/10
Creatinine increasedInvestigations0/92/10
HypercalcemiaMetabolism and nutrition disorders0/92/10
DizzinessNervous system disorders1/90/10
Back painMusculoskeletal and connective tissue disorders0/91/10
AnemiaBlood and lymphatic system disorders0/91/10
HyponatremiaMetabolism and nutrition disorders0/91/10
Chronic kidney diseaseRenal and urinary disorders0/91/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Kava InterventionPlacebo ControlTotal
<=18 years000
Between 18 and 65 years8917
>=65 years112
Age, Continuous
Age, Continuous(years)Kava InterventionPlacebo ControlTotal
Mean56.44 (49 to 68)57.9 (45 to 70)57.21 (45 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Kava InterventionPlacebo ControlTotal
Female7916
Male213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Kava InterventionPlacebo ControlTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American055
White9514
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Kava InterventionPlacebo ControlTotal
United States91019
08

Study locations

1 site
  • University of Florida
    Gainesville, Florida 32608, United States
09

References and documents

Publications

  • Freeman B, Bian T, Xu G, Wheeler M, Fujioka N, Malaty J, Orlando FA, Braithwaite D, Salloum RG, Bruijnzeel AW, Zhang W, Xing C. Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions. Carcinogenesis. 2026 Apr 9;47(2):bgag031. doi: 10.1093/carcin/bgag031. PubMed 42142878 ↗
  • Xing C, Malaty J, Malham MB, Nehme AMA, Freeman B, Huo Z, Firpi-Morrel R, Salloum RG. Reducing tobacco-associated lung cancer risk: a study protocol for a randomized clinical trial of AB-free kava. Trials. 2023 Jan 18;24(1):36. doi: 10.1186/s13063-023-07081-x. PubMed 36653872 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2025, 36 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Oct 18, 2021
StartActual
Jun 9, 2022
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Sep 3, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05081882
Collaborators
Florida Department of Health
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Jun 9, 2022
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Sep 3, 2026
Last update
Sep 3, 2026

Study contacts

Ramzi Salloum, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piper methysticum root

Start the discussion